View Older Stories
-
Cosmos Health (COSM) files for 74.66M share offering by selling stockholders
-
Cosmos Health reports Q3 revenue exceeds $17 million amid US expansion
-
Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy
-
Cosmos Health reports record quarterly revenue of $17 million
-
Cosmos Health is Forcing the Market to Reframe the Conversation
-
Cosmos Health CEO purchases 3.4 million shares year-to-date
-
Cosmos Health (COSM) Misses Q3 EPS by 2c
-
Cosmos Health reports Q3 revenue up 38% to $17.1 million
-
Cosmos Health (COSM) files $200M mixed shelf
-
Cosmos Health starts nanotechnology program for supplement formulas
-
Cosmos Health purchases additional $200,000 in Ethereum under digital facility
-
Cosmos Health buys additional $300,000 in ethereum, total reaches $1.8 million
-
Cosmos Health buys additional $500,000 in ethereum
-
Cosmos Health signs Kuwait distribution deal for nutraceuticals
-
Cosmos Health (COSM) CEO Greg Siokas issues letter to shareholders
-
Cosmos Health launches U.S. nutraceuticals operations with Sky Premium Life
-
Cosmos Health signs distribution deal for Oman nutraceuticals market
-
Cosmos Health (COSM) Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech
-
Cosmos Health (COSM) Receives Nasdaq Extension to Regain Compliance
-
Cosmos Health (COSM) CEO Acquires $526K in Shares Past Week
-
Cosmos Health (COSM) Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBIT
-
Cosmos Health (COSM) Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order
-
Cosmos Health (COSM) Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates
-
Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates
-
Cosmos Health (COSM) will not Proceed with an Offering Under Its Form S-1
-
Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1
-
Cosmos Health (COSM) Enters Final Development Phase of CCX0722
-
Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market
-
Cosmos Health (COSM) Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies
-
Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market
-
Cosmos Health (COSM) appoints Dimitris Moraitis as VP of Strategy and Operations
-
Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations
-
Cosmos Health (COSM) Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products
-
Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Bac
-
Cosmos Health (COSM) recieves purchase order of $578,460 from Al Rabwa
-
Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar
-
Cosmos Health (COSM) Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market
-
Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market
-
Cosmos Health (COSM) Secures Bond Loan from European Bank on Very Competitive Terms, with Option to Upsize to Support Growth and Achieve Positive Operating Cash Flow
-
Cosmos Health Secures Bond Loan from European Bank on Very Competitive Terms, with Option to Upsize to Support Growth and Achieve Positive Operating Cash Flow
-
Cosmos Health (COSM) Submits Patent Application for Allergic Inflammation Therapy
-
Cosmos Health Submits Patent Application for Allergic Inflammation Therapy by Leveraging AI Drug Repurposing; Allergy Treatment Market Valued at $23.5 Billion
-
Cosmos Health (COSM) Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait
-
Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait
-
Cosmos Health (COSM) Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers, Valued at Over $24.5M
-
Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers, Valued at Over $24.5 Million
-
Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days
-
Cosmos Health (COSM) Secures Exclusive Distribution Agreement with Virax Biolabs (VRAX) for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Coun
-
Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries
-
Cosmos Health (COSM) Appoints Dimitrios Trafalis as Head of Oncology
